The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
This is the first drug to receive a recommendation for this preventative indication in the European Union
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Fenebrutinib targets cells in the immune system known as B cells and microglia
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
Subscribe To Our Newsletter & Stay Updated
